Antibody Information
General Information of This Antibody
Antibody ID | ANI0OVZUV |
|||||
---|---|---|---|---|---|---|
Antibody Name | Anti-MSL1 mAb |
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Humanized IgG1-kappa |
|||||
Antigen Name | Male-specific lethal 1 homolog (MSL1) |
Antigen Info |
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Anti-MSL1 mAb-Compound 31 [Investigative]
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
37.38 nM
|
Positive MSL expression (MSL+++/++) | ||
Method Description |
The cells were incubated in a CO2 incubat or with saturated water overnight, On the second day, two covalent thiol conjugated ADCs were serially diluted conjugates were added to the 96 well plate containing OVCAR3 cells, 100uL per well. The initial conjugate was 100000 ng/ml and diluted to 0.001 ng/ml. OVCAR3 cells with added ADC were incubated at 37 for 72 hours.
Click to Show/Hide
|
||||
In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 |
Anti-MSL1 mAb-Compound 75 [Investigative]
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
50.00 nM
|
Positive MSL expression (MSL+++/++) | ||
Method Description |
The cells were incubated in a CO2 incubat or with saturated water overnight, On the second day, two covalent thiol conjugated ADCs were serially diluted conjugates were added to the 96 well plate containing OVCAR3 cells, 100uL per well. The initial conjugate was 100000 ng/ml and diluted to 0.001 ng/ml. OVCAR3 cells with added ADC were incubated at 37 for 72 hours.
Click to Show/Hide
|
||||
In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.